Get the Stockscreener App
0.1994
46.62%
0.0634
After Hours:
.28
0.0806
+40.42%
Gossamer Bio Inc stock is traded at $0.1994, with a volume of 306.99M.
It is up +46.62% in the last 24 hours and up +27.01% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.136
Open:
$0.17345
24h Volume:
306.99M
Relative Volume:
16.24
Market Cap:
$97.48M
Revenue:
$55.54M
Net Income/Loss:
$-180.40M
P/E Ratio:
-0.2531
EPS:
-0.7877
Net Cash Flow:
$-170.32M
1W Performance:
+41.42%
1M Performance:
+27.01%
6M Performance:
-92.45%
1Y Performance:
-89.16%
1-Day Range:
$0.145
$0.2142
1-Week Range:
$0.1321
$0.2142
52-Week Range:
$0.1138
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1994 | 66.48M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver Quantitative
Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingView
Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom - TechStock²
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Benzinga
GOSS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocus
Gossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo Finance
Gossamer Bio stock surges 25% on FDA regulatory update - Investing.com
GOSS: Key Regulatory and Corporate Developments Announced - GuruFocus
Why is Gossamer Bio stock surging today? By Investing.com - Investing.com Canada
Gossamer Bio plans September NDA submission for seralutinib By Investing.com - Investing.com Nigeria
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire
Gossamer Bio Inc (GOSS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
$Gossamer Bio (GOSS.US)$ - Moomoo
GOSS|Gossamer Bio Inc|Price:0.147|Chg%:+0.011 - TradingKey
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gossamer Bio, Inc. Revenue Breakdown – NASDAQ:GOSS - TradingView
Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB - TradingView
GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006 - TradingKey
Form 13D/A Gossamer Bio For: 24 July By Investing.com - Investing.com Nigeria
Gossamer Bio Inc (GOSS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ETFs Investing in Gossamer Bio, Inc. Stocks - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook - Ad-hoc-news.de
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio(GOSS) Stock Options Chain | Quotes & News - Moomoo
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Remains KeyPost-Announcement Reaction - dars.gov.et
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - AOL.com
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB - TradingView
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio (GOSS) Income Statement & Earnings - Moomoo
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - AOL.com
Gossamer Bio (GOSS) Q1 2025 earnings summary - Quartr
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes - Global Legal Chronicle
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - AOL.com
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - AOL.com
Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations - Ad-hoc-news.de
GOSSGossamer Bio Inc Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to earnings forward of Gossamer Bio, Inc. – DUS:4GB - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
GOSS Should I Buy - Intellectia AI
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):